Immunoparalysis and Adverse Outcomes from Critical Illness

Pediatric Clinics of North America

Volumn 55, Issue 3, 2008, Pages 647-668

  Frazier, W Joshua ^a,b   Hall, Mark W ^a,b  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTOKINE; TACROLIMUS;

ADAPTIVE IMMUNITY; COMPENSATORY ANTIINFLAMMATORY RESPONSE SYNDROME; CRITICAL ILLNESS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOPARALYSIS; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INJURY; INNATE IMMUNITY; MONOCYTE; NONHUMAN; ORGAN TRANSPLANTATION; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

CRITICAL ILLNESS; HUMANS; IMMUNITY, NATURAL; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC DEFICIENCY SYNDROMES; INCIDENCE; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 43949122548     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2008.02.009     Document Type: Review

References (102)

1. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. The Intravenous Immunoglobulin Collaborative Study Group. N Engl J Med 327 4 (1992) 234-240
2. Calandra T., Glauser M.P., Schellekens J., et al. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. J Infect Dis 158 2 (1988) 312-319
3. Bone R.C., Balk R.A., Fein A.M., et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 23 6 (1995) 994-1006
4. Greenman R.L., Schein R.M., Martin M.A., et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 266 8 (1991) 1097-1102
5. McCloskey R.V., Straube R.C., Sanders C., et al. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 121 1 (1994) 1-5
6. Fisher Jr. C.J., Dhainaut J.F., Opal S.M., et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271 23 (1994) 1836-1843
7. Opal S.M., Fisher Jr. C.J., Dhainaut J.F., et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 25 7 (1997) 1115-1124
8. Abraham E., Anzueto A., Gutierrez G., et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 351 9107 (1998) 929-933
9. Abraham E., Wunderink R., Silverman H., et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273 12 (1995) 934-941
10. Cohen J., and Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 24 9 (1996) 1431-1440
11. Panacek E.A., Marshall J.C., Albertson T.E., et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 32 11 (2004) 2173-2182
12. Fein A.M., Bernard G.R., Criner G.J., et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA 277 6 (1997) 482-487
13. Docke W.D., Syrbe U., Meinecke A., et al. Improvement in monocyte function: a new therapeutic approach in sepsis?. In: Reinhart K., Eyrich K., and Sprung C. (Eds). Sepsis: current perspectives in pathophysiology and therapy (1994), Springer-Verlag, Berlin 473-500
14. Monneret G., Lepape A., Voirin N., et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 32 8 (2006) 1175-1183
15. Ho Y.P., Sheen I.S., Chiu C.T., et al. A strong association between down-regulation of HLA-DR expression and the late mortality in patients with severe acute pancreatitis. Am J Gastroenterol 101 5 (2006) 1117-1124
16. Polk Jr. H.C., Wellhausen S.R., and Regan M. A systematic study of host defense processes in badly injured patients. Ann Surg 204 3 (1986) 282-297
17. Hershman M.J., Cheadle W.G., Wellhausen S.R., et al. Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient. Br J Surg 77 2 (1990) 204-207
18. Livingston D.H., Appel S.H., Wellhausen S.R., et al. Depressed interferon gamma production and monocyte HLA-DR expression after severe injury. Arch Surg 123 11 (1988) 1309-1312
19. Chatila T.A. Role of regulatory T cells in human diseases. J Allergy Clin Immunol 116 5 (2005) 949-959 [quiz: 960]
20. Calandra T., Gerain J., Heumann D., et al. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med 91 1 (1991) 23-29
21. Doughty L.A., Kaplan S.S., and Carcillo J.A. Inflammatory cytokine and nitric oxide responses in pediatric sepsis and organ failure. Crit Care Med 24 7 (1996) 1137-1143
22. Ghani R.A., Zainudin S., Ctkong N., et al. Serum IL-6 and IL-1-ra with sequential organ failure assessment scores in septic patients receiving high-volume haemofiltration and continuous venovenous haemofiltration. Nephrology (Carlton) 11 5 (2006) 386-393
23. Pinsky M.R., Vincent J.L., Deviere J., et al. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 103 2 (1993) 565-575
24. Steensberg A., Fischer C.P., Keller C., et al. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab 285 2 (2003) E433-E437
25. Diehl S., and Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 39 9 (2002) 531-536
26. Goldstein B., Giroir B., and Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 6 1 (2005) 2-8
27. Docke W.D., Hoflich C., Davis K.A., et al. Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem 51 12 (2005) 2341-2347
28. Majetschak M., Flach R., Kreuzfelder E., et al. The extent of traumatic damage determines a graded depression of the endotoxin responsiveness of peripheral blood mononuclear cells from patients with blunt injuries. Crit Care Med 27 2 (1999) 313-318
29. Majetschak M., Krehmeier U., Bardenheuer M., et al. Extracellular ubiquitin inhibits the TNF-alpha response to endotoxin in peripheral blood mononuclear cells and regulates endotoxin hyporesponsiveness in critical illness. Blood 101 5 (2003) 1882-1890
30. Hall M.W., and Carcillo J.A. Immune paralysis and the state of immunologic dissonance in pediatric multiple organ dysfunction syndrome. Crit Care Med 29 12 (2001) A20
31. Docke W.D., Randow F., Syrbe U., et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3 6 (1997) 678-681
32. Flach R., Majetschak M., Heukamp T., et al. Relation of ex vivo stimulated blood cytokine synthesis to post-traumatic sepsis. Cytokine 11 2 (1999) 173-178
33. Heagy W., Nieman K., Hansen C., et al. Lower levels of whole blood LPS-stimulated cytokine release are associated with poorer clinical outcomes in surgical ICU patients. Surg Infect (Larchmt) 4 2 (2003) 171-180
34. Wolk K., Docke W., von Baehr V., et al. Comparison of monocyte functions after LPS- or IL-10-induced reorientation: importance in clinical immunoparalysis. Pathobiology 67 5-6 (1999) 253-256
35. Wolk K., Docke W.D., von Baehr V., et al. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 96 1 (2000) 218-223
36. Randow F., Syrbe U., Meisel C., et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J Exp Med 181 5 (1995) 1887-1892
37. Bundschuh D.S., Barsig J., Hartung T., et al. Granulocyte-macrophage colony-stimulating factor and IFN-gamma restore the systemic TNF-alpha response to endotoxin in lipopolysaccharide-desensitized mice. J Immunol 158 6 (1997) 2862-2871
38. Flohe S., Dominguez Fernandez E., Ackermann M., et al. Endotoxin tolerance in rats: expression of TNF-alpha, IL-6, IL-10, VCAM-1 AND HSP 70 in lung and liver during endotoxin shock. Cytokine 11 10 (1999) 796-804
39. Madonna G.S., Peterson J.E., Ribi E.E., et al. Early-phase endotoxin tolerance: induction by a detoxified lipid A derivative, monophosphoryl lipid A. Infect Immun 52 (1986) 6-11
40. Bohuslav J., Kravchenko V.V., Parry G.C., et al. Regulation of an essential innate immune response by the p50 subunit of NF-kappaB. J Clin Invest 102 9 (1998) 1645-1652
41. Kastenbauer S., and Ziegler-Heitbrock H.W. NF-kappaB1 (p50) is upregulated in lipopolysaccharide tolerance and can block tumor necrosis factor gene expression. Infect Immun 67 4 (1999) 1553-1559
42. Wahlstrom K., Bellingham J., Rodriguez J.L., et al. Inhibitory kappaBalpha control of nuclear factor-kappaB is dysregulated in endotoxin tolerant macrophages. Shock 11 4 (1999) 242-247
43. Nakayama K., Okugawa S., Yanagimoto S., et al. Involvement of IRAK-M in peptidoglycan-induced tolerance in macrophages. J Biol Chem 279 8 (2004) 6629-6634
44. Escoll P., del Fresno C., Garcia L., et al. Rapid up-regulation of IRAK-M expression following a second endotoxin challenge in human monocytes and in monocytes isolated from septic patients. Biochem Biophys Res Commun 311 2 (2003) 465-472
45. del Fresno C., Otero K., Gomez-Garcia L., et al. Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol 174 5 (2005) 3032-3040
46. Dobrovolskaia M.A., and Vogel S.N. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect 4 9 (2002) 903-914
47. Alves-Rosa F., Vulcano M., Beigier-Bompadre M., et al. Interleukin-1beta induces in vivo tolerance to lipopolysaccharide in mice. Clin Exp Immunol 128 2 (2002) 221-228
48. Medvedev A.E., Lentschat A., Wahl L.M., et al. Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. J Immunol 169 9 (2002) 5209-5216
49. Fumeaux T., and Pugin J. Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med 166 11 (2002) 1475-1482
50. Pangault C., Le Tulzo Y., Tattevin P., et al. Down-modulation of granulocyte macrophage-colony stimulating factor receptor on monocytes during human septic shock. Crit Care Med 34 4 (2006) 1193-1201
51. Pachot A., Lepape A., Vey S., et al. Systemic transcriptional analysis in survivor and non-survivor septic shock patients: a preliminary study. Immunol Lett 106 1 (2006) 63-71
52. Hall M.W., Gavrilin M.A., Knatz N.L., et al. Monocyte mRNA phenotype and adverse outcomes from pediatric multiple organ dysfunction syndrome. Pediatr Res 62 5 (2007) 597-603
53. Le Tulzo Y., Pangault C., Amiot L., et al. Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock. Am J Respir Crit Care Med 169 10 (2004) 1144-1151
54. Volk T., Schmutzler M., Engelhardt L., et al. Influence of aminosteroid and glucocorticoid treatment on inflammation and immune function during cardiopulmonary bypass. Crit Care Med 29 11 (2001) 2137-2142
55. Monneret G., Debard A.L., Venet F., et al. Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med 31 7 (2003) 2068-2071
56. Venet F., Pachot A., Debard A.L., et al. Increased percentage of CD4+CD25+ regulatory T cells during septic shock is due to the decrease of CD4+CD25- lymphocytes. Crit Care Med 32 11 (2004) 2329-2331
57. Hotchkiss R.S., Tinsley K.W., Swanson P.E., et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 166 11 (2001) 6952-6963
58. Felmet K.A., Hall M.W., Clark R.S., et al. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol 174 6 (2005) 3765-3772
59. Westendorp R.G., Langermans J.A., Huizinga T.W., et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349 9046 (1997) 170-173
60. Cheadle W.G., Wilson M., Hershman M.J., et al. Comparison of trauma assessment scores and their use in prediction of infection and death. Ann Surg 209 5 (1989) 541-545 [discussion: 545-6]
61. Volk H.D., Reinke P., Krausch D., et al. Monocyte deactivation-rationale for a new therapeutic strategy in sepsis. Intensive Care Med 22 Suppl 4 (1996) S474-S481
62. Hall M.W., Volk H.D., and Carcillo J.A. Immune paralysis in pediatric multiple organ dysfunction syndrome. Pediatr Res 47 4 (2000) 57A
63. Perry S.E., Mostafa S.M., Wenstone R., et al. Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis?. Intensive Care Med 29 8 (2003) 1245-1252
64. Ploder M., Pelinka L., Schmuckenschlager C., et al. Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock 25 2 (2006) 129-134
65. Allen M.L., Peters M.J., Goldman A., et al. Early postoperative monocyte deactivation predicts systemic inflammation and prolonged stay in pediatric cardiac intensive care. Crit Care Med 30 5 (2002) 1140-1145
66. Allen M.L., Hoschtitzky J.A., Peters M.J., et al. Interleukin-10 and its role in clinical immunoparalysis following pediatric cardiac surgery. Crit Care Med 34 10 (2006) 2658-2665
67. Randow F., Docke W.D., Bundschuh D.S., et al. In vitro prevention and reversal of lipopolysaccharide desensitization by IFN-gamma, IL-12, and granulocyte-macrophage colony-stimulating factor. J Immunol 158 6 (1997) 2911-2918
68. Borgermann J., Friedrich I., Scheubel R., et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) restores decreased monocyte HLA-DR expression after cardiopulmonary bypass. Thorac Cardiovasc Surg 55 1 (2007) 24-31
69. Wysocka M., Montaner L.J., and Karp C.L. Flt3 ligand treatment reverses endotoxin tolerance-related immunoparalysis. J Immunol 174 11 (2005) 7398-7402
70. Hershman M.J., Appel S.H., Wellhausen S.R., et al. Interferon-gamma treatment increases HLA-DR expression on monocytes in severely injured patients. Clin Exp Immunol 77 1 (1989) 67-70
71. Flohe S., Borgermann J., Dominguez F.E., et al. Influence of granulocyte-macrophage colony-stimulating factor (GM-CSF) on whole blood endotoxin responsiveness following trauma, cardiopulmonary bypass, and severe sepsis. Shock 12 1 (1999) 17-24
72. Lendemans S., Kreuzfelder E., Waydhas C., et al. Differential immunostimulating effect of granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and interferon gamma (IFNgamma) after severe trauma. Inflamm Res 56 1 (2007) 38-44
73. Kox W.J., Bone R.C., Krausch D., et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med 157 4 (1997) 389-393
74. Docke W., Syrbe U., Meinecke A., et al. Improvement in monocyte function: a new therapeutic approach?. In: Reinhart K., Eyrich K., and Sprung C. (Eds). Sepsis: current perspectives in pathophysiology and therapy (1994), Springer-Verlag, New York 473-500
75. Nakos G., Malamou-Mitsi V.D., Lachana A., et al. Immunoparalysis in patients with severe trauma and the effect of inhaled interferon-gamma. Crit Care Med 30 7 (2002) 1488-1494
76. Nierhaus A., Montag B., Timmler N., et al. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med 29 4 (2003) 646-651
77. Bilgin K., Yaramis A., Haspolat K., et al. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics 107 1 (2001) 36-41
78. Rosenbloom A.J., Linden P.K., Dorrance A., et al. Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients. Chest 127 6 (2005) 2139-2150
79. Carr R., Modi N., and Dore C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst Rev 3 (2003) CD003066
80. Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 49 RR-10 (2000) 1-125
81. Hempel L., Korholz D., Nussbaum P., et al. High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation. Bone Marrow Transplant 20 5 (1997) 365-368
82. Gras J., Wieers G., Vaerman J.L., et al. Early immunological monitoring after pediatric liver transplantation: cytokine immune deviation and graft acceptance in 40 recipients. Liver Transpl 13 3 (2007) 426-433
83. Settmacher U., Docke W.D., Manger T., et al. Management of induction phase of immunosuppression in liver graft recipients: prevention of oversuppression by immune monitoring. Transplant Proc 25 4 (1993) 2703-2704
84. Reinke P., and Volk H.D. Diagnostic and predictive value of an immune monitoring program for complications after kidney transplantation. Urol Int 49 2 (1992) 69-75
85. Hoffman J.A., Weinberg K.I., Azen C.G., et al. Human leukocyte antigen-DR expression on peripheral blood monocytes and the risk of pneumonia in pediatric lung transplant recipients. Transpl Infect Dis 6 4 (2004) 147-155
86. Denzel C., Riese J., Hohenberger W., et al. Monitoring of immunotherapy by measuring monocyte HLA-DR expression and stimulated TNFalpha production during sepsis after liver transplantation. Intensive Care Med 24 12 (1998) 1343-1344
87. Trindade E., Maton P., Reding R., et al. Use of granulocyte macrophage colony stimulating factor in children after orthotopic liver transplantation. J Hepatol 28 6 (1998) 1054-1057
88. Pizzo P.A., Rubin M., Freifeld A., et al. The child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategies. J Pediatr 119 5 (1991) 679-694
89. Kaplan J.E., Masur H., and Holmes K.K. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 51 RR-8 (2002) 1-52
90. Benson C.A., Kaplan J.E., Masur H., et al. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep 53 RR-15 (2004) 1-112
91. Marik P.E., and Raghavan M. Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 30 5 (2004) 748-756
92. Jaber B.L., Cendoroglo M., Balakrishnan V.S., et al. Apoptosis of leukocytes: basic concepts and implications in uremia. Kidney Int Suppl 78 (2001) S197-S205
93. Massry S., and Smogorzewski M. Dysfunction of polymorphonuclear leukocytes in uremia: role of parathyroid hormone. Kidney Int Suppl 78 (2001) S195-S196
94. Woiciechowsky C., Schoning B., Lanksch W.R., et al. Mechanisms of brain-mediated systemic anti-inflammatory syndrome causing immunodepression. J Mol Med 77 11 (1999) 769-780
95. Woiciechowsky C., and Volk H.D. Increased intracranial pressure induces a rapid systemic interleukin-10 release through activation of the sympathetic nervous system. Acta Neurochir Suppl 95 (2005) 373-376
96. Bergmann M., and Sautner T. Immunomodulatory effects of vasoactive catecholamines. Wien Klin Wochenschr 114 17-18 (2002) 752-761
97. Dandona P., Aljada A., Mohanty P., et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?. J Clin Endocrinol Metab 86 7 (2001) 3257-3265
98. Singhal P.C., Kapasi A.A., Franki N., et al. Morphine-induced macrophage apoptosis: the role of transforming growth factor-beta. Immunology 100 1 (2000) 57-62
99. Yuengsrigul A., Chin T.W., and Nussbaum E. Immunosuppressive and cytotoxic effects of furosemide on human peripheral blood mononuclear cells. Ann Allergy Asthma Immunol 83 6 Pt 1 (1999) 559-566
100. Kanakoudi-Tsakalidou F., Debonera F., Drossou-Agakidou V., et al. Flow cytometric measurement of HLA-DR expression on circulating monocytes in healthy and sick neonates using monocyte negative selection. Clin Exp Immunol 123 3 (2001) 402-407
101. Yerkovich S.T., Wikstrom M.E., Suriyaarachchi D., et al. Postnatal Development of Monocyte Cytokine Responses to Bacterial Lipopolysaccharide. Pediatr Res 62 5 (2007) 547-552
102. El-Mohandes A.A., Rivas R.A., Kiang E., et al. Membrane antigen and ligand receptor expression on neonatal monocytes. Biol Neonate 68 5 (1995) 308-317